Heterogeneous c-Met Activation in Osteosarcoma Dictates Synergistic Vulnerability to Combined c-Met Inhibition and Methotrexate Therapy
PHA665752 combined with MTX synergistically inhibits OS cell growth <i>via</i> dual suppression of c-Met signaling (PI3K/AKT, MAPK/ERK). and MTX-mediated cytotoxicity, highlighting the potential of co-targeting overlapping pathways to enhance OS treatment efficacy.
Authors
- Hiroyuki Kawashima (ORCID: https://orcid.org/0000-0001-9511-9773)
- Naoki Oike (ORCID: https://orcid.org/0000-0003-3067-392X)
- Guidong Li (ORCID: https://orcid.org/0000-0003-2800-4452)
- Akira Ogose (ORCID: https://orcid.org/0000-0001-6204-0110)
- Takashi Ariizumi (ORCID: https://orcid.org/0000-0002-0777-1612)
- Taro Sasaki (ORCID: https://orcid.org/0000-0003-3289-4080)
Institutions
- Saiseikai Niigata Daini Hospital (JP)
- Niigata University (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-06-27
- DOI
- https://doi.org/10.21873/anticanres.17648
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00